Based on 6 analysts giving stock ratings to Eledon Pharmaceuticals Inc in the past month.
In the current month, ELDN has received 4 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. ELDN average Analyst price target in the last month is 9.000.
Based on analysts' estimates, ELDN EPS is projected to reach -0.164 in FY2026Q4, following reported EPS of -0.034 in FY2026Q3. Track earnings expectations against reported figures to see how profitability is evolving.
The market expectation was USD -0.03, while Eledon Pharmaceuticals IncELDN's earnings per share (EPS) for the previous quarter was USD -0.28. EPS for the next quarter is expected at USD -0.16.